High efficacy of BPaL among patients infected with Mycobacterium tuberculosis lineage 1 in the Philippines
Authors:
Open Access
- 1 April 2026
- journal article
- Published by International Union Against Tuberculosis and Lung Disease in IJTLD OPEN
- Vol. 3 (4) , 226-231
Abstract
SUMMARY: BACKGROUND: WHO recommends the bedaquiline–pretomanid–linezolid regimen with/without moxifloxacin (M) (BPaL/M) for the treatment of multidrug- or rifampicin-resistant TB. However, Mycobacterium tuberculosis (MTB) lineage 1 (L1) is less susceptible to pretomanid than other lineages, and there are limited BPaL/M efficacy data from regions where L1 is prevalent. METHODS: We performed whole genome sequencing (WGS) on baseline MTB isolates from a subgroup (34/103) of patients from the highly successful Philippine BPaL Operational Research Study to characterise their lineage and genotypic drug susceptibility testing (DST) profile. Phenotypic DST for BPaL drugs was also conducted. RESULTS: WGS analysis showed that L1 (68%) predominated, followed by L4 (26%) and L2 (6%). Out of the 22 L1 isolates tested, 20 exhibited higher pretomanid minimum inhibitory concentrations than isolates from other lineages, including one with borderline resistance. Two patients had confirmed bedaquiline resistance; no linezolid resistance was detected. All 34 patients with characterised isolates had culture converted by end of treatment. At month 12 follow-up, 30/31 patients who provided sputum remained culture negative; the single culture-positive participant harboured MTB L4. CONCLUSION: In this study, patients infected with MTB L1 responded to BPaL as well as those infected with other lineages. Baseline bedaquiline resistance was linked to the unique recurrence in the study.Keywords
This publication has 21 references indexed in Scilit:
- Effectiveness and safety of the BPaL regimen in the PhilippinesJournal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2025
- Balancing promise and peril: risk management in India's BPaL introductionThe Lancet Infectious Diseases, 2025
- Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical TrialClinical Infectious Diseases, 2024
- Whole genome sequencing analysis of Mycobacterium tuberculosis reveals circulating strain types and drug-resistance mutations in the PhilippinesScientific Reports, 2024
- Bedaquiline: what might the future hold?The Lancet Microbe, 2024
- Drug-resistant tuberculosis: a persistent global health concernNature Reviews Microbiology, 2024
- The use of BPaL containing regimen in the MDR/PreXDR TB treatments in ThailandJournal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2023
- Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort studyThe Lancet Microbe, 2023
- Estimation of the global burden of Mycobacterium tuberculosis lineage 1Infection, Genetics and Evolution, 2021
- Mycobacterium tuberculosis whole genome sequencing provides insights into the Manila strain and drug-resistance mutations in the PhilippinesScientific Reports, 2019